참고문헌 (36)

1. 1 Ruhl CE Everhart JE Epidemiology of nonalcoholic fatty liver Clin Liver Dis 2004 8 501 519 15331060 

   상세보기

2. 2 Vanni E Bugianesi E Kotronen A De Minicis S Yki-Jarvinen H Svegliati-Baroni G From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010 42 320 330 20207596 

3. 3 Kim CH Younossi ZM Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome Cleve Clin J Med 2008 75 721 728 18939388 

4. 4 Kim W Egan JM The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 2008 60 470 512 19074620 

   상세보기

5. 5 MacDonald PE El-Kholy W Riedel MJ Salapatek AM Light PE Wheeler MB The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion Diabetes 2002 51 Suppl 3 S434 S442 12475787 

6. 6 Ahren B Schmitz O GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes Horm Metab Res 2004 36 867 876 15655721 

   상세보기

7. 7 Bourdel-Marchasson I Schweizer A Dejager S Incretin therapies in the management of elderly patients with type 2 diabetes mellitus Hosp Pract (Minneap) 2011 39 7 21 21441754 

8. 8 Ding X Saxena NK Lin S Gupta NA Anania FA Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice Hepatology 2006 43 173 181 16374859 

9. 9 Gupta NA Mells J Dunham RM Grakoui A Handy J Saxena NK Anania FA Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway Hepatology 2010 51 1584 1592 20225248 

10. 10 Sharma S Mells JE Fu PP Saxena NK Anania FA GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy PLoS One 2011 6 e25269 21957486 

11. 11 Adiels M Taskinen MR Boren J Fatty liver, insulin resistance, and dyslipidemia Curr Diab Rep 2008 8 60 64 18367000 

12. 12 Donnelly KL Smith CI Schwarzenberg SJ Jessurun J Boldt MD Parks EJ Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease J Clin Invest 2005 115 1343 1351 15864352 

    상세보기

13. 13 Liu Q Bengmark S Qu S The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD) Lipids Health Dis 2010 9 42 20426802 

14. 14 Reddy JK Rao MS Lipid metabolism and liver inflammation II Fatty liver disease and fatty acid oxidation Am J Physiol Gastrointest Liver Physiol 2006 290 G852 G858 16603729 

15. 15 Musso G Gambino R Cassader M Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD) Prog Lipid Res 2009 48 1 26 18824034 

    상세보기

16. 16 Pettinelli P Del Pozo T Araya J Rodrigo R Araya AV Smok G Csendes A Gutierrez L Rojas J Korn O Maluenda F Diaz JC Rencoret G Braghetto I Castillo J Poniachik J Videla LA Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion Biochim Biophys Acta 2009 1792 1080 1086 19733654 

17. 17 Shimomura I Bashmakov Y Horton JD Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus J Biol Chem 1999 274 30028 30032 10514488 

    상세보기

18. 18 Pratley RE The new science of GLP-1: effects beyond glucose control Johns Hopkins Adv Stud Med 2008 8 393 399 

19. 19 Lee J Hong SW Chae SW Kim DH Choi JH Bae JC Park SE Rhee EJ Park CY Oh KW Park SW Kim SW Lee WY Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice PLoS One 2012 7 e31394 22363635 

    상세보기

20. 20 Tushuizen ME Bunck MC Pouwels PJ van Waesberghe JH Diamant M Heine RJ Incretin mimetics as a novel therapeutic option for hepatic steatosis Liver Int 2006 26 1015 1017 16953843 

    상세보기

21. 21 Svegliati-Baroni G Saccomanno S Rychlicki C Agostinelli L De Minicis S Candelaresi C Faraci G Pacetti D Vivarelli M Nicolini D Garelli P Casini A Manco M Mingrone G Risaliti A Frega GN Benedetti A Gastaldelli A Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis Liver Int 2011 31 1285 1297 21745271 

    상세보기

22. 22 Lee YS Shin S Shigihara T Hahm E Liu MJ Han J Yoon JW Jun HS Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis Diabetes 2007 56 1671 1679 17369525 

    상세보기

23. 23 Tomas E Wood JA Stanojevic V Habener JF GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice Regul Pept 2011 169 43 48 21549160 

    상세보기

24. 24 Shirakawa J Fujii H Ohnuma K Sato K Ito Y Kaji M Sakamoto E Koganei M Sasaki H Nagashima Y Amo K Aoki K Morimoto C Takeda E Terauchi Y Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice Diabetes 2011 60 1246 1257 21330637 

    상세보기

25. 25 Bechmann LP Hannivoort RA Gerken G Hotamisligil GS Trauner M Canbay A The interaction of hepatic lipid and glucose metabolism in liver diseases J Hepatol 2012 56 952 964 22173168 

    상세보기

26. 26 Hettema EH Tabak HF Transport of fatty acids and metabolites across the peroxisomal membrane Biochim Biophys Acta 2000 1486 18 27 10856710 

27. 27 Minnich A Tian N Byan L Bilder G A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle Am J Physiol Endocrinol Metab 2001 280 E270 E279 11158930 

28. 28 Hashimoto T Fujita T Usuda N Cook W Qi C Peters JM Gonzalez FJ Yeldandi AV Rao MS Reddy JK Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype J Biol Chem 1999 274 19228 19236 10383430 

29. 29 Canto C Auwerx J PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure Curr Opin Lipidol 2009 20 98 105 19276888 

30. 30 Ruderman NB Xu XJ Nelson L Cacicedo JM Saha AK Lan F Ido Y AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab 2010 298 E751 E760 20103737 

    상세보기

31. 31 Shen Z Liang X Rogers CQ Rideout D You M Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice Am J Physiol Gastrointest Liver Physiol 2010 298 G364 G374 20007851 

32. 32 Hou X Xu S Maitland-Toolan KA Sato K Jiang B Ido Y Lan F Walsh K Wierzbicki M Verbeuren TJ Cohen RA Zang M SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase J Biol Chem 2008 283 20015 20026 18482975 

    상세보기

33. 33 Canto C Gerhart-Hines Z Feige JN Lagouge M Noriega L Milne JC Elliott PJ Puigserver P Auwerx J AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity Nature 2009 458 1056 1060 19262508 

    상세보기

34. 34 Klonoff DC Buse JB Nielsen LL Guan X Bowlus CL Holcombe JH Wintle ME Maggs DG Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin 2008 24 275 286 18053320 

    상세보기

35. 35 Zheng D Ionut V Mooradian V Stefanovski D Bergman RN Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver Diabetes 2009 58 352 359 19011168 

    상세보기

36. 36 Park S Hong SM Ahn IS Exendin-4 and exercise improve hepatic glucose homeostasis by promoting insulin signaling in diabetic rats Metabolism 2010 59 123 133 19766272 

    상세보기